Isomorphic Labs
AI-driven drug discovery solutions
CORE INFO
Isomorphic Labs is a biotechnology company based in London that uses AI to enhance drug discovery and development, collaborating with major pharmaceutical firms to create new medicines.
- Isomorphic Labs raised $2.1 billion in a Series B funding round led by Thrive Capital in May 2026.forbes.com
- The company collaborates with pharmaceutical giants like Johnson & Johnson to apply its AI technologies in drug development.techcrunch.com
WHY WE WOULD WORK AT ISOMORPHIC LABS
Transform Drug Discovery
Join a mission to revolutionize drug discovery with AI-driven solutions like the Drug Design Engine (IsoDDE), enhancing the speed and accuracy of identifying viable drug candidates.
Cutting-Edge Technology
Work with advanced AI models built on DeepMind's AlphaFold technology, pushing the boundaries of protein structure prediction and molecular design.
Collaborate with Leaders
Partner with major pharmaceutical companies like Eli Lilly and Novartis, contributing to groundbreaking therapeutics that can change lives.
Significant Funding
Benefit from robust financial backing, including $2.1 billion in Series B funding, enabling ambitious growth and innovation in AI drug discovery.
Impact on Human Health
Play a crucial role in advancing human health by modeling fundamental life mechanisms, aiming to tackle diseases through innovative AI applications.
Interdisciplinary Team Culture
Be part of a collaborative environment where drug discovery experts and machine learning specialists work together to drive meaningful advancements in healthcare.
MARKET AND TRACTION
TOTAL ADDRESSABLE MARKET
NOTABLE CUSTOMERS
KEY METRICS
✦ KEY METRICGROWTH TACTICS
COMPETITIVE ADVANTAGE
PRODUCT AND TECH
AI-Driven Drug Discovery
Isomorphic Labs specializes in utilizing advanced AI models to predict protein structures and interactions, significantly accelerating the drug discovery process. This approach allows for the rapid design of novel molecules, enhancing the efficiency of identifying viable drug candidates.
Drug Design Engine (IsoDDE)
The IsoDDE is the company's flagship product, a unified AI drug design engine that improves the accuracy and efficiency of drug candidate identification. It leverages cutting-edge AI technologies to streamline the drug development pipeline, making it a critical tool for pharmaceutical companies.
Protein Structure Prediction
Building on DeepMind's AlphaFold technology, Isomorphic Labs employs sophisticated AI models to predict protein folding and interactions. This capability is essential for understanding biological processes and designing effective therapeutics.
Strategic Pharmaceutical Collaborations
Isomorphic Labs collaborates with major pharmaceutical companies, including Eli Lilly and Novartis, to apply its AI technologies in developing new therapeutics. These partnerships not only enhance the drug discovery process but also have the potential to generate significant milestone payments.
AI-First Approach
The company's mission is to reimagine drug discovery through an AI-first approach, aiming to model and understand fundamental mechanisms of life. This innovative perspective positions Isomorphic Labs at the forefront of transforming how new medicines are developed.